Alnylam Pharmaceuticals, Inc. (ALNY) Given “Overweight” Rating at Piper Jaffray Companies

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s stock had its “overweight” rating reiterated by equities research analysts at Piper Jaffray Companies in a research note issued to investors on Wednesday. They presently have a $116.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $110.00. Piper Jaffray Companies’ price objective suggests a potential upside of 1.95% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the company. Needham & Company LLC boosted their target price on Alnylam Pharmaceuticals from $85.00 to $125.00 in a research note on Wednesday. Chardan Capital set a $110.00 price objective on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, June 12th. BidaskClub cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 29th. Jefferies Group LLC reiterated a “buy” rating and set a $102.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Thursday, June 22nd. Finally, Credit Suisse Group set a $96.00 price objective on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, July 11th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $87.59.

Alnylam Pharmaceuticals (ALNY) traded up 51.71% during trading on Wednesday, reaching $113.84. The company had a trading volume of 18,362,421 shares. The company’s market capitalization is $10.44 billion. Alnylam Pharmaceuticals has a 52-week low of $31.38 and a 52-week high of $116.93. The company has a 50 day moving average price of $81.14 and a 200 day moving average price of $69.12.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by ($0.12). The firm had revenue of $15.93 million during the quarter, compared to the consensus estimate of $23.86 million. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The company’s revenue was up 82.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.05) EPS. On average, equities analysts forecast that Alnylam Pharmaceuticals will post ($5.19) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Alnylam Pharmaceuticals, Inc. (ALNY) Given “Overweight” Rating at Piper Jaffray Companies” was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://stocknewstimes.com/2017/09/20/alnylam-pharmaceuticals-inc-alny-given-overweight-rating-at-piper-jaffray-companies.html.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Broadfin Capital LLC acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at $14,453,000. Verition Fund Management LLC acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at $1,060,000. The Manufacturers Life Insurance Company grew its holdings in Alnylam Pharmaceuticals by 7.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 167 shares in the last quarter. EcoR1 Capital LLC acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at $831,000. Finally, BlueCrest Capital Management Ltd acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at $1,304,000. 94.25% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply